About this trial
This trial will compare ivosidenib and enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy
Patient Profile
Patients with newly diagnosed diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, St James’s Hospital, and University Hospital Galway
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | HOVON 150 |
|---|---|
| Number: | 19-18 |
| Full Title: | A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy. |
| Principal Investigator: | Dr Catherine Flynn (St. James's Hospital) |
|---|---|
| Type: | Collaborative |
| Sponsor: | Collaborative Group Trial sponsored by HOVON (based in The Netherlands) |
| Recruitment Started: |
Global: March 2019 Ireland: May 2021 |
| Global Recruitment Target: | 968 |
|---|---|
| Ireland Recruitment Target: | 40 |